
Cancer-Related Micro-RNAs May Serve as MM Bone Disease Biomarkers
Two cancer-related micro-RNAs could serve as prognostic biomarkers for multiple myeloma bone disease as lower levels were associated with lower overall survival rates, investigators concluded.
Among the several cancer-related micro-RNAs (miRNAs) found to have an association with
Results of the quantitative investigational study searching for MM biomarkers,
“We provide evidence that miR-16-5p and miR-155-5p merit further investigation as diagnostic biomarkers, able to discriminate between MM and sMM,” wrote the investigators.
MM occurs in 1.0% to 1.8% of all malignancies and is the second most common
In the bone marrow microenvironment, exosomes carrying
The investigators collected bone marrow samples from 76 patients who were newly diagnosed with MM at the Department of Clinical Therapeutics at the Alexandria General Hospital in Athens, Greece. The median age of the patients was 68 years, 57.9% were men, and 75 patients were receiving an MM therapy. Moreover, 21 patients underwent autologous stem cell transplantation following high-dose melphalan and 55 patients were ineligible for a bone marrow transplant.
Optimized quantitative polymerase-chain reaction assays were developed for the quantification of each miRNA sample. CD138+ plasma cells were selected from the bone marrow samples and total RNA was extracted and polyadenylated in vitro . The investigators also conducted a functional in silico analysis of the miRNAs.
Results from the Mann-Whitney U test found a statistically significant reduction in the levels of miR-16-5p and miR-155-5p in the CD138+ plasma cells of patients with MM (P = .036) in comparison with patients with sMM (P = .045). For miR-155-5p, a mean (SD) of 366.0 (167.6) relative quantification units (RQU) was observed in the CD138+ cells in patients with MM compared with 1285.7 (539.8) RQU in the cells from patients with sMM.
Additionally, lower levels of miR-15a-5p (P = .037), miR-16-5p (P = .035), and miR-222-3p (P = .037) were detected in the CD138+ plasma cells derived from patients with MM with osteolytic bone lesions compared with patients without lesions.
In reference to miR-15a-5p, a mean (SD) of 7.71 (3.25) RQU was observed in patients with osteolytic lesions compared with 29.93 (12.66) RQU in patients without the lesions. In patients with bone disease who presented with skeletal-related events, miR-125b-5p was found to be overexpressed in their CD138+ plasma cells.
The results also showed that miR-223-3p could offer favorable prognostic value in MM as lower levels of miR-223-3p were associated with significantly worse overall survival in patients with MM.
The small cohort size and short follow-up times were listed as study limitations. However, the investigators noted that their cohort was representative of the general MM population.
Reference
Papanota A, Karousi P, Kontos CK, et al. A cancer-related microRNA signature shows biomarker utility in multiple myeloma. Int J Mol Sci. 2021;22(23):12144. doi:10.3390/ijms222313144
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.